查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1659424

下一代癌症诊断药物的全球市场

Next Generation Cancer Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，美国下一代癌症诊断的全球市场规模预计将达到 646 亿美元

2024 年全球下一代癌症诊断市场规模估计为 198 亿美元，预计 2030 年将达到 646 亿美元，2024-2030 年分析期间的复合年增长率为 21.8%。 qPCR 和多路復用技术是报告中分析的细分市场之一，预计到分析期结束时复合年增长率为 22.8%，达到 282 亿美元。预计分析期间次世代定序技术领域的复合年增长率为 17.9%。

美国市场规模估计为 57 亿美元，中国市场预计复合年增长率为 21.0%

美国新一代癌症诊断市场规模预计在2024年达到57亿美元。中国是世界第二大经济体，预计到 2030 年市场规模将达到 99 亿美元，2024-2030 年分析期间的复合年增长率为 21.0%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 19.3% 和 18.0%。在欧洲，预计德国的复合年增长率约为 14.8%。

全球下一代癌症诊断市场 - 主要趋势和驱动因素摘要

下一代癌症诊断技术如何彻底改变肿瘤学？

下一代癌症诊断（NGCD）代表了肿瘤学领域的突破，为各种癌症的早期检测、精准诊断和个人化治疗提供了先进的工具。这些诊断方法涵盖了广泛的技术，包括液态切片、基因组学、蛋白质组学和次世代定序（NGS）。与传统诊断不同，NGCD 提供详细的分子见解，使肿瘤学家能够了解驱动癌症进展的基因突变和生物标记。这种精确度可以实现标靶治疗，改善患者的治疗效果并减少副作用。随着全球癌症发生率的上升，NGCD 透过提供更个人化、更快速、更有效的癌症治疗，在转变癌症治疗方面发挥关键作用。

下一代癌症诊断市场的关键部分是什么？

关键技术包括液态切片、NGS、蛋白质组学和生物资讯学工具，其中液态切片和NGS因其非侵入性和检测基因改变的能力而获得了显着的关注。在应用方面，NGCD用于筛检、诊断测试和治疗反应的监测。筛检早期癌症（例如乳癌、肺癌和大肠癌）是一个主要应用领域，早期发现可以显着提高存活率。 NGCD 的主要终端使用者包括医院、诊断实验室和研究机构，他们都将这些技术整合到他们的临床工作流程中，以提高癌症管理的准确性和效率。

NGCD 技术如何融入医疗保健领域？

医院和肿瘤中心正在将 NGCD 纳入常规癌症筛检和诊断方案中，特别是针对高风险患者和患有遗传性癌症症候群的患者。诊断实验室使用 NGCD 进行基因组和蛋白质组学测试，以帮助识别特定的突变和治疗方案，以支持精准医疗。研究机构利用这些诊断方法进行临床试验、研究癌症基因体学并发现新的药物标靶。製药公司也与 NGCD 开发商合作，识别可预测药物疗效的生物标记物，从而改善药物开发并加速临床试验。此外，远端医疗平台开始融入NGCD，实现远端患者监护，让癌症诊断变得更容易。

哪些因素将推动下一代癌症诊断市场的成长？

下一代癌症诊断市场的成长受到多种因素的推动，包括癌症发生率的上升，这推动了对更有效的筛检和诊断工具的需求。基因组学和蛋白​​质组学的进步推动了个人化医疗的转变，进一步刺激了 NGCD 的采用。液态切片技术的快速发展，加上NGS平台的改进，提高了诊断的准确性，使得NGS在现代肿瘤学中变得至关重要。此外，监管部门的核准和政府对癌症研究和诊断创新的资助也促进了市场的成长。此外，人们对早期癌症检测的认识不断提高以及基因检测服务的扩展正在推动整个医疗保健行业对 NGCD 的需求。

部分

技术（qPCR 和多路復用、次世代定序、LOAC 和 RT-PCR、其他技术）、功能（治疗监测、伴同性诊断、预后诊断、癌症筛检、风险分析）、应用（生物标记开发、CTC 分析、蛋白质组学分析、基因分析、其他应用）

受访公司范例（值得关注的33家公司）

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips NV
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP22375

Global Next Generation Cancer Diagnostics Market to Reach US$64.6 Billion by 2030

The global market for Next Generation Cancer Diagnostics estimated at US$19.8 Billion in the year 2024, is expected to reach US$64.6 Billion by 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing Technology, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 17.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 21.0% CAGR

The Next Generation Cancer Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.3% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global Next Generation Cancer Diagnostics Market - Key Trends and Drivers Summarized

How Are Next Generation Cancer Diagnostics Revolutionizing Oncology?

Next Generation Cancer Diagnostics (NGCD) represent a leap forward in the field of oncology, offering advanced tools for early detection, accurate diagnosis, and personalized treatment of various cancers. These diagnostics encompass a broad range of technologies, including liquid biopsy, genomics, proteomics, and next-generation sequencing (NGS). Unlike traditional diagnostics, NGCDs provide detailed molecular insights, enabling oncologists to understand the genetic mutations and biomarkers that drive cancer progression. This precision enables targeted therapies, improving patient outcomes and reducing side effects. As the prevalence of cancer rises globally, NGCDs are playing a critical role in transforming cancer care by making it more personalized, faster, and more effective.

What Are The Key Segments in the Next Generation Cancer Diagnostics Market?

Key technologies include liquid biopsy, NGS, proteomics, and bioinformatics tools, with liquid biopsy and NGS gaining significant traction due to their non-invasive nature and ability to detect genetic alterations. In terms of applications, NGCDs are used in screening, diagnostic testing, and monitoring treatment response. Screening for early-stage cancers, such as breast, lung, and colorectal cancers, is a major application segment, where early detection significantly improves survival rates. Major end-users of NGCDs include hospitals, diagnostic laboratories, and research institutes, all of which are integrating these technologies into clinical workflows to enhance precision and efficiency in cancer management.

How Are NGCD Technologies Being Integrated Across Healthcare Sectors?

Hospitals and oncology centers are integrating NGCDs into routine cancer screening and diagnostic protocols, particularly for high-risk patients and those with hereditary cancer syndromes. Diagnostic laboratories use NGCDs to perform genomic and proteomic tests that aid in identifying specific mutations and treatment options, supporting precision medicine. Research institutes are leveraging these diagnostics to conduct clinical trials, study cancer genomics, and explore new drug targets. Pharmaceutical companies also collaborate with NGCD developers to identify biomarkers that predict drug efficacy, thereby improving drug development and accelerating clinical trials. Additionally, telehealth platforms are beginning to incorporate NGCDs for remote patient monitoring, making cancer diagnostics more accessible.

What Factors Are Driving the Growth in the Next Generation Cancer Diagnostics Market?

The growth in the Next Generation Cancer Diagnostics market is driven by several factors, including the increasing prevalence of cancer, which has heightened the demand for more effective screening and diagnostic tools. The shift toward personalized medicine, driven by advancements in genomics and proteomics, has further fueled the adoption of NGCDs. The rapid development of liquid biopsy technologies, coupled with improvements in NGS platforms, has enhanced diagnostic accuracy, making NGCDs indispensable in modern oncology. Regulatory approvals and government funding for cancer research and diagnostic innovation are also contributing to market growth. Additionally, the growing awareness of early cancer detection and the expansion of genetic testing services have increased the demand for NGCDs across healthcare sectors.

SCOPE OF STUDY:

The report analyzes the Next Generation Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR, Other Technologies); Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis); Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Next Generation Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Early and Accurate Cancer Detection Spurs Growth in Next Generation Cancer Diagnostics Market
    • Technological Advancements in Liquid Biopsy and Genomic Testing Strengthen Business Case for Adoption
    • Growing Focus on Personalized and Precision Medicine Expands Addressable Market
    • Expansion of Next Generation Diagnostics in Oncology Clinics and Hospitals Fuels Market Growth
    • Increasing Adoption of Next Generation Diagnostics in Biomarker Discovery and Targeted Therapy Expands Market Opportunities
    • Technological Innovations in Multi-Omics Analysis and AI-Powered Diagnostics Propel Market Expansion
    • Rising Focus on Non-Invasive Testing and Monitoring Drives Demand for Next Generation Cancer Diagnostics
    • Growing Use of Next Generation Diagnostics in Screening Programs and Clinical Trials Expands Market Potential
    • Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth
    • Increasing Focus on Integrating Next Generation Cancer Diagnostics with Digital Health Platforms Drives Adoption
    • Rising Demand for Companion Diagnostics in Immuno-Oncology and Targeted Therapies Strengthens Global Market
    • Expansion of Next Generation Cancer Diagnostics in Rare and Pediatric Cancers Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for qPCR & Multiplexing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for qPCR & Multiplexing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for LOAC & RT-PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for LOAC & RT-PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biomarker Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Biomarker Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Proteomic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Proteomic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Genetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Therapeutic Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Therapeutic Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Recent Past, Current & Future Analysis for Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 28: World 6-Year Perspective for Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Risk Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World 6-Year Perspective for Risk Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 31: World Next Generation Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • JAPAN
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CHINA
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • EUROPE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • FRANCE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 64: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • GERMANY
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ITALY
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 82: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030

IV. COMPETITION